Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Budesonid + Formoterol, (ausschl. IHP in der Wirkstärke 80 µg/4,5 µg), ATC R03AK07 f. d Z. 1.10.26-30.09.28

Section 130a, paragraph 8 of the German Social Code Book V (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Competition Act (GWB) is carried out by DAK-Gesundheit. For the pharmaceuticals to be specified by the bidder in more detail in Annex 2 to the contract, containing the aforementioned active substance Budesonid and Formoterol (exclusively IHP in the strength 80µg /4.5 µg), ATC R03AK07, DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the authorisation model for the aforementioned active substance will come into force for the first time on 01.10.2026 and will end on 30.09.2028 (plus extension option 1x12 months). It will end automatically with the entry into force of the exclusive contract, regardless.